NasdaqGS:RGENLife Sciences
Repligen (RGEN) Return To Profitability Tests Bullish Growth Narrative In Q4 2025 Results
Repligen (RGEN) closed out FY 2025 with Q4 revenue of US$197.9 million and basic EPS of US$0.24, alongside net income of US$13.3 million, giving investors a clear snapshot of its latest quarterly performance. Over recent periods, the company has seen revenue move from US$167.5 million in Q4 2024 to US$197.9 million in Q4 2025, while basic EPS shifted from a loss of US$0.60 to a profit of US$0.24. This set up a year where trailing twelve month EPS reached US$0.87 on revenue of US$738.3 million...